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Research
Despite improvements in environmental 
  policies and significant reductions in average 
U.S. blood lead levels, lead exposure remains 
a concern for pregnant and lactating women. 
This is particularly true among certain popu-
lation subgroups at increased risk, such as 
women from developing countries and 
those with occupational exposures [Centers 
for Disease Control and Prevention (CDC) 
2007; Meyer et al. 2003]. In addition, overall 
declines in environmental sources highlight 
maternal bone as a long-lived endogenous 
source of exposure that poses a potential 
hazard for the developing fetus and breast-
feeding infant (Hu and Hernández-Avila 
2002). Redistribution of cumulative maternal 
bone lead stores into the circulation occurs 
during periods of increased bone resorption, 
such as pregnancy and lactation (Gulson et al. 
2003; Manton et al. 2003; Téllez-Rojo et al. 
2004). Prenatal lead exposure has adverse 
influences on infant birth and neurodevelop-
mental outcomes across a wide range of expo-
sure (Bellinger 2005; Hu et al. 2006), and 
maternal bone lead has been shown to be an 
independent risk factor (Gomaa et al. 2002; 
Gonzalez-Cossío et al. 1997; Hernández-
Avila et al. 2002).
The potential role of nutrition in altering 
susceptibility to lead exposure and toxicity has 
long been recognized (Aub et al. 1932; Hu 
et al. 1995; Mahaffey 1974, 1990). Dietary 
intake concurrent to exposure is known to 
have an impact on lead dynamics, and nutri-
ents may interact with lead by binding lead 
in the gut, competing with lead for absorp-
tion, altering intestinal cell avidity for lead, 
and altering affinity of target tissues for lead 
(Ballew and Bowman 2001).
Inadequate calcium consumption has 
been shown to increase lead absorption 
(Heard and Chamberlain 1982) and reten-
tion (Six and Goyer 1970). Lead competes 
with calcium at calcium-binding sites and 
may subsequently alter protein function and 
calcium homeostasis (Sauk and Somerman 
1991). Evidence indicates that low dietary 
calcium and vitamin D are risk factors for 
elevated bone lead levels (Cheng et al. 1998). 
Higher milk intake during pregnancy also 
has been associated with lower maternal and 
umbilical cord lead levels in postpartum 
women (Hernández-Avila et al. 1997), sug-
gesting that calcium status may be an impor-
tant factor in the maternal–fetal transfer of 
lead across the placenta.
Calcium requirements are increased sub-
stantially during pregnancy and lactation in 
order to meet the needs of the developing 
fetus and nursing infant for skeletal mineral-
ization and growth (Prentice 2000). Maternal 
calcium homeostasis is maintained by con-
trolling intestinal calcium absorption, renal 
calcium excretion, and mobilization of skele-
tal mineral stores (Kovacs and Kronenberg 
1997). The role of dietary calcium and min-
eral adequacy on skeletal changes of preg-
nancy and lactation is controversial; however, 
it is recommended that pregnant and breast-
feeding women consume 1,000–1,300 mg 
calcium per day, depending on their age 
(Institute of Medicine 1997).
In a randomized, double-blind, placebo-
controlled trial of 1,200 mg daily calcium 
supplementation in lactating women, we have 
previously shown that calcium supplementa-
tion reduced maternal blood lead by 15–20% 
(Hernández-Avila et al. 2003) and breast milk 
lead by 5–10% (Ettinger et al. 2006) over the 
course of lactation. Our objective in the pres-
ent study was to evaluate the effect of 1,200 
mg daily calcium supplementation on mater-
nal blood lead levels during pregnancy, the 
period of greater relevance for maternal–fetal 
transfer of lead.
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ba c K g r O u n d: Prenatal lead exposure is associated with deficits in fetal growth and neurodevelop-
ment. Calcium supplementation may attenuate fetal exposure by inhibiting mobilization of maternal 
bone lead and/or intestinal absorption of ingested lead.
Ob j e c t i v e: Our goal was to evaluate the effect of 1,200 mg dietary calcium supplementation on 
maternal blood lead levels during pregnancy.
me t h O d s : In a double-blind, randomized, placebo-controlled trial conducted from 2001 through 
2003 in Mexico City, we randomly assigned 670 women in their first trimester of pregnancy to 
ingest calcium (n = 334) or placebo (n = 336). We followed subjects through pregnancy and evalu-
ated the effect of supplementation on maternal blood lead, using an intent-to-treat analysis by a 
mixed-effects regression model with random intercept, in 557 participants (83%) who completed 
follow-up. We then conducted as-treated analyses using similar models stratified by treatment 
compliance.
re s u l t s: Adjusting for baseline lead level, age, trimester of pregnancy, and dietary energy and cal-
cium intake, calcium was associated with an average 11% reduction (0.4 µg/dL) in blood lead level 
relative to placebo (p = 0.004). This reduction was more evident in the second trimester (–14%, 
p < 0.001) than in the third (–8%, p = 0.107) and was strongest in women who were most compli-
ant (those who consumed ≥ 75% calcium pills; –24%, p < 0.001), had baseline blood lead > 5 µg/dL 
(–17%, p < 0.01), or reported use of lead-glazed ceramics and high bone lead (–31%, p < 0.01).
cO n c l u s i O n: Calcium supplementation was associated with modest reductions in blood lead when 
administered during pregnancy and may constitute an important secondary prevention effort to 
reduce circulating maternal lead and, consequently, fetal exposure.
Key w O r d s : calcium, diet, lead, pregnancy, randomized trial, supplementation. Environ Health 
Perspect 117:26–31 (2009).  doi:10.1289/ehp.11868 available via http://dx.doi.org/ [Online 
2 September 2008]Calcium supplementation and blood lead in pregnancy
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Materials and Methods
Study population and design. We recruited 
pregnant women from 2001 through 2003 
at the Mexican Social Security Institute 
(Instituto Mexicano del Seguro Social) pre-
natal clinics that serve a low- to moderate-
income popu  lation in Mexico City. We 
assessed 3,836 women for eligibility, of whom 
1,981 did not meet study eligibility criteria 
(pregnancy of no more than 14 weeks’ gesta-
tion; not presenting with a high-risk preg-
nancy; plans to reside in the metropolitan 
Mexico City area for ~ 5 years) or had other 
reasons not being enrolled (n = 2). Of the 
remaining 1,853 eligible women, 670 (36%) 
agreed to participate and signed the informed 
consent, and were randomly assigned to 
receive a daily supplement of 1,200 mg cal-
cium [two 600-mg calcium carbonate tab-
lets (Wyeth Consumer Health Care/Lederle 
Laboratories, Inc., México City, México) 
at bedtime; n = 334] or placebo (n = 336). 
We assessed blood lead levels, dietary cal-
cium intake, and reported use of lead-glazed 
ceramics (LGC) at three time points: baseline 
(first trimester), 6 months (second trimester), 
and 8 months (third trimester). We assessed 
compliance by pill count at each follow-up 
visit. We defined women who had at least one 
blood lead measurement at 6 or 8 months’ 
gestation (n = 565; 84%) as having completed 
follow-up. Eight women did not have baseline 
blood lead levels, yielding a total of 557 sub-
jects (83%) available for inclusion in the final 
analyses (Figure 1).
The research protocol was approved by the 
Human Subjects Committee of the National 
Institutes of Public Health, the Mexican Social 
Security Institute, the Brigham and Women’s 
Hospital, and the Harvard School of Public 
Health and complied with both Mexican and 
U.S. federal guidelines governing the use of 
human participants. All participating mothers 
received a detailed explanation of the study 
intent and procedures and were advised on 
identifying and avoiding LGC pottery use 
during pregnancy before signing the approved 
written informed consent.
Blood lead measurement. Blood lead meas-
urements(1.0 µg/dL = 0.0483 µmol/L) were 
performed using graphite furnace atomic 
absorption spectrophotometry (Perkin-Elmer 
model 3000; Norwalk, CT, USA) at the 
American British Cowdray (ABC) Hospital 
Trace Metal Laboratory according to a tech-
nique described in Miller et al. (1987). The 
laboratory participates in the CDC blood lead 
proficiency testing program administered by 
the Wisconsin State Laboratory of Hygiene 
(Madison, WI, USA) and maintained accept-
able precision and accuracy over the study 
period.
Bone lead measurement. At 1 month 
postpartum (± 5 days), maternal bone lead 
was estimated by a spot-source cadmium-109 
K-X-ray fluorescence (K-XRF) instrument 
at the research facility at the ABC Hospital. 
We used two 30-min in vivo measurements 
of each subject’s mid-tibial shaft (representing 
cortical bone) and patella (trabecular bone). 
The physical principles, technical specifica-
tions, validation, and use of the K-XRF tech-
nique have been described in detail elsewhere 
(Chettle et al. 2003; Hu et al. 1998). For 
quality control, we excluded bone lead meas-
urements with uncertainty estimates > 10 
and 15 µg lead/g mineral bone for tibia and 
patella, respectively.
Dietary intake. We assessed maternal 
dietary intake in each trimester of pregnancy 
using a semiquantitative food frequency ques-
tionnaire designed to estimate usual dietary 
intake over the prior month. We based the 
questionnaire on the semiquantitative food 
frequency questionnaires and validation 
methodology used in the Harvard Nurses’ 
Health Study and Health Professionals’ 
Follow-up Study (Willett et al. 1985, 1987). 
We translated the questionnaire and validated 
it for use specifically for the Mexican Spanish-
speaking adult population (Hernández-Avila 
et al. 1998).
Statistical analysis. We compared base-
line characteristics of participants between the 
calcium and placebo groups using Wilcoxon 
rank-sum (Mann–Whitney U-test) two-sample 
test of equality or Student’s t-test, as appro-
priate. We performed a similar comparison 
between those included in the analyses and 
those lost to follow-up.
We evaluated the effect of calcium sup-
plement on blood lead concentration using 
an intent-to-treat analysis by means of a 
mixed-effects regression model with a ran-
dom intercept for each subject. This approach 
takes into account the within-subject cor-
relation structure attributed to the repeated 
measurements, yielding valid standard errors 
of the effect estimates. Blood lead concentra-
tions in the second and third trimester of 
pregnancy were the outcome variables; how-
ever, we used models featuring natural-log– 
transformed blood lead because this param-
eterization provided the best fit. In order 
not to exclude very low blood lead concen-
trations from the analysis, we substituted 
27 blood lead meas  ure  ments (1.6% of the 
total) below the limit of detection (1 µg/dL) 
with random numbers following a uniform 
distribution between 0 and 1. We adjusted 
models for the following baseline variables: 
first trimester log-transformed blood lead 
concentration, maternal age (years), treat-
ment group, daily calcium (grams per day) 
and energy intake (kilo  calories per day), and 
trimester of pregnancy.
To assess the overall intent-to-treat effect 
of calcium supplementation on blood lead 
Figure 1. Study sample profile.
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concentrations throughout the last two 
  trimesters of pregnancy, we fitted the follow-
ing model:
  ln(BPbij) = (α + ui) + β1Si + β2IBPbi 
    + β3Cai + β4Ci 
    + β5Ai + β6Tj + εi,j,  [1]
where ln(BPbi,j) is the loge-transformed 
blood lead concentration for subject i at tri-
mester j, α + ui denotes the random intercept 
where ui represents the error term associated 
to the ith subject [i = (1, 2, . . . , n); ui ~ n(0, 
σ2
u)], Si is a dummy variable that indicates 
treatment assignment, lnBPbi is the initial 
(baseline) natural log-transformed blood lead 
concentration of the ith subject, Tj is the 
jth trimester of pregnancy [j = (2,3)], Ci is 
the baseline daily energy intake, Cai is the 
baseline daily calcium dietary intake, Ai is 
age, and εi,j denotes the random variation 
[εi,j ~ n(0, σ2)]. The overall treatment effect 
estimate is the coefficient β1.
We fitted a second model to estimate the 
treatment effect at each trimester:
  ln(BPbij) = (α + ui) + β1Si + β2IBPbi 
   + β3Cai + β4Cj + β5Ai  
   + β6Tj + β7SiTj + εij,  [2]
where SiTj denotes the interaction term 
between blood lead levels and trimester of 
pregnancy. The treatment effect estimate in 
the second trimester is the coefficient β1, and 
the effect in the third trimester is (β1 + β7).
We used a secondary dose–response study 
to further assess the effectiveness of supple-
mentation. We assessed compliance by pill 
count at each visit and analyzed it as pro-
portion of expected pills used between base-
line (first trimester) and end of follow-up 
(8 months’ gestation). We defined treatment 
compliance group in three ways: ≥ 50% of 
pills consumed, ≥ 67% of pills consumed, and 
≥ 75% of pills consumed. To try to disentan-
gle the effect of calcium supplementation on 
bone lead mobilization versus gastrointestinal 
absorption, we developed models with an 
interaction model for postpartum bone lead 
levels and reported use of LGC. The rationale 
for fitting this model was that the effect of 
the supplement may have been larger in those 
who had larger bone lead concentration and/
or in those who used LGC. We generated a 
new dummy variable designating high and 
low patella bone lead levels dichotomized 
at the median (5.6 µg/g) and created a two-
way interaction term with LGC use (yes/no). 
We did not include a three-way interaction 
because we found no reason to think that 
the magnitude of the effect of bone lead con-
centrations, and thus bone lead mobilization 
rates, on blood lead would depend on the use 
of LGC. We fitted the following model:
  lnPbit = β0 + β1Si + β2BPbi  
    + β3LGCit + δ1SiBPbi  
   + δ2SiLGCit + covariatesi + εit,  [3]
where Pbit is blood lead concentration for the 
ith subject at the tth trimester, Si is the sup-
plementation group, BPbi is the first available 
postpartum bone lead measurement, LGCit is 
current use of LGC in the ith subject at the 
tth trimester, and δ1 represents the difference 
in the effect of supplementation between the 
high and low bone Pb concentration groups, 
and δ2 represents the difference in the effect 
of supplementation between the current use/
not use of LGC groups. Covariates are base-
line blood lead level, baseline daily calcium 
dietary intake, baseline daily energy intake, 
age, and trimester of pregnancy. Because we 
were trying to disentangle biologic mecha-
nisms, we restricted these models to those 
who with ≥ 75% compliance.
Finally, to account for possible heteroge-
neity of treatment effects according to initial 
blood lead levels, we also performed analysis 
by baseline blood lead group (< 5 µg/dL vs. 
≥ 5 µg/dL) using an intent-to-treat analy-
sis and then among only those women with 
≥ 50% compliance.
We performed all statistical analyses using 
Stata for Windows (version 9.0; StataCorp 
LP, College Station, TX, USA).
Table 1. Baseline characteristics of participants, by treatment assignment and follow-up status. 
  Treatment assignment  Follow-up status
Variable  Calcium (n = 334)  Placebo (n = 336)  Completeda (n = 565)  Lost (n = 105)
Age (years)  26.9 ± 5.6  25.9 ± 5.3b  26.5 ± 5.5  26.2 ± 5.4
Education (years)  10.8 ± 2.9  10.6 ± 2.9  10.7 ± 2.9  10.7 ± 2.8
No. of pregnancies  2.0 ± 1.0  2.1 ± 1.1  2.1 ± 1.1  2.0 ± 0.9
Weight (kg)  61.9 ± 10.7  61.5 ± 10.0  61.6 ± 10.2  62.2 ± 11.0
Height (cm)  154.4 ± 5.6  154.4 ± 5.9  154.3 ± 5.8  155.0 ± 5.8
Dietary calcium intake (g/day)  0.92 ± 0.35  0.89 ± 0.40  0.90 ± 0.38  0.94 ± 0.34
Total energy intake (kcal/day)  2,213 ± 632  2,157 ± 675  2,155 ± 642  2,347 ± 699b
Current use of LGC [no. (%)]   117 (35%)  115 (34%)  205 (36%)  27 (26%)b
Blood lead (µg/dL)c  3.8 (2.0)  4.1 (2.0)  3.8 (2.0)  4.5 (1.9)
Values are mean ± SD except where noted.
aCompleted follow-up defined as having at least one follow-up blood lead level at 6 or 8 months of pregnancy. bp < 0.05 
Student’s t-test or Wilcoxon rank-sum (Mann–Whitney U-test) two-sample test of equality for difference in means or chi-
square test, as appropriate. cGeometric mean (geometric standard deviation) blood lead levels.
Table 2. Effect of calcium supplementation on blood lead concentration (log-transformed) (n = 557; intent-
to-treat analysis).
Variable  β-Coefficient  p-Value  95% CI
Treatment (calcium = 1; placebo = 0)  –0.117  0.004  (–0.196 to –0.038)
Blood lead at baseline (µg/dL)a  0.674  < 0.001  (0.165 to 0.732)
Age (years)  0.007  0.051  (–0.00003 to 0.014)
Dietary calcium intake at baseline (g/day)  –0.024  0.751  (–0.169 to 0.122)
Total energy intake at baseline (1,000 kcal/day)  –0.010  0.813  (–0.096 to 0.075)
Trimester of pregnancy (time: 1 = third; 0 = second)  0.119  < 0.001  (0.073 to 0.166)
aLog-transformed outcome variable, thus estimate of treatment effect: 1 – e–0.117 = –11% (95% CI, –17.8% to –3.7%).
Table 3. Effect of calcium supplementationa by treatment compliance.b
  Average (Overall)  Second trimester  Third trimester
Compliance  No.  β % Δc  p-Value  β % Δc  p-Value  β % Δc  p-Value
All  557  –0.12  –11%  0.004  –0.15  –14%  0.001  –0.08  –8%  0.107
< 50%  82  0.18  20%  0.115  0.30  35%  0.024  0.09  9%  0.497
≥ 50%  475  –0.17  –15%  < 0.001  –0.22  –20%  < 0.001  –0.11  –10%  0.037
≥ 67%  357  –0.20  –19%  < 0.001  –0.28  –24%  < 0.001  –0.12  –11%  0.054
≥ 75%  241  –0.27  –24%  < 0.001  –0.32  –27%  < 0.001  –0.21  –19%  0.004
aAdjusted for baseline blood lead level, maternal age, dietary calcium intake at baseline, daily energy intake at baseline, 
treatment group, and trimester of pregnancy. bWe assessed compliance by pill count at each visit and analyzed it as 
proportion of expected pills used between baseline (first trimester) and end of follow-up (8 months’ gestation). cPercent 
change; log-transformed outcome variable, thus estimate of treatment effect: 1 – e–β.
Figure 2. Effect of calcium supplementation on 
maternal blood lead at each trimester during preg-
nancy among the high-compliance group (≥ 75% 
of pills by pill count, adjusting for baseline blood 
lead, age, dietary calcium intake, and daily energy 
intake.
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Results
We randomized 670 eligible women to receive 
calcium supplementation (n = 334) or placebo 
(n = 336) (Figure 1). Baseline characteristics 
were largely similar for both the calcium and 
placebo groups. Mean maternal age was 1 year 
higher in the control group (26.9 years) than 
in the calcium group (25.9 years; p = 0.02) 
(Table 1). Approximately 35% of women 
reported current use of traditional LGC for 
storing, preparing, or serving food; however, 
we found no significant differences by treat-
ment group. Dietary calcium intake, also not 
significantly different between the two groups, 
was about 900 mg/day on average. Geometric 
mean (and geometric standard deviation) 
prerandomization blood lead levels were 3.8 
(2.0) and 4.1 (2.0) µg/dL for the calcium and 
placebo groups, respectively (p = 0.05).
A total of 565 women (84%) completed 
follow-up. Comparing the group that com-
pleted follow-up (placebo n = 277; calcium 
n = 288) with those lost to follow-up [placebo 
n = 59 (18%); calcium n = 46 (14%)], we 
found no significant differences by treatment 
group assignment (p = 0.18). Those women 
who remained in the study reported higher 
daily energy intake (p < 0.01) and higher use 
of LGC (p = 0.04) at baseline. Those women 
who completed follow-up reported higher cur-
rent use of LGC (36%) than those who did 
not complete follow-up (26%); among those 
completing follow-up, however, we found no 
significant differences in reported LGC use by 
treatment group.
In the intent-to-treat analysis (n = 557), cal-
cium supplementation was associated with an 
overall average reduction of 11% in maternal 
blood lead concentrations relative to placebo 
(p = 0.004) (Table 2). In a secondary analysis, 
this reduction was more evident in the second 
trimester (14% reduction, p < 0.001) than in 
the third trimester (8% reduction, p = 0.107). 
These results did not change when we con-
trolled for hematocrit level (data not shown).
When we assessed the dose–response 
effect of calcium supplementation for women 
“as treated” (n = 557) using models strati-
fied by treatment compliance, we saw a clear 
dose–response effect of calcium on blood 
lead concentration (Table 3). Among those 
women who consumed ≥ 50% of pills, cal-
cium was associated on average with a 15% 
reduction in blood lead levels compared 
with those taking placebo (p < 0.001). This 
increased to 19% (p < 0.001) and 24% (p < 
0.001) for those who consumed ≥ 67% of 
pills and ≥ 75% of pills, respectively (p for 
trend < 0.001). Figure 2 shows the effects of 
calcium and placebo on maternal blood lead 
over time among the high-compliance group.
Among the low-compliance group 
(< 50% of pills consumed), blood lead was 
higher in the calcium-supplemented group, 
suggesting that these women were somehow 
different from the low compliers receiving 
placebo. In fact, in the group that completed 
follow-up (n = 565), those with low com-
pliance reported higher current use of LGC 
in the calcium group (35%) compared with 
placebo (27%), which might explain the 
apparent increase in blood lead among the 
low-compliance group. We found no signifi-
cant differences in reported LGC use among 
the high-compliance group.
Figure 3 shows the proportional reduc-
tion [and 95% confidence intervals (CIs)] 
in blood lead due to calcium supplementa-
tion, stratified by use of LGC and patella 
lead level, among the high-compliance group. 
Among women consuming ≥ 75% of pills, 
those with high patella bone lead experi-
enced greater reductions than those women 
with lower bone lead levels, corresponding 
to a 23% reduction (p = 0.01) for those with 
no reported use of LGC and a 31% reduc-
tion (p < 0.01) for those who reported use 
of LGC. In this subset of most compliant 
women with high patella bone lead (> 5 µg/g) 
and reported use of LGC, the effect cor-
responds to an average blood lead reduction 
of 1.95 µg/dL (95% CI, –0.78 to –2.87).
We repeated the analysis by baseline blood 
lead group (< 5 µg/dL vs. ≥ 5 µg/dL) using 
intent-to-treat and as-treated analyses among 
only those women with compliance ≥50% 
of pills consumed (Table 4). The effects of 
calcium appeared stronger in the group with 
higher blood lead at baseline (17% reduc-
tion), compared with those with baseline 
blood lead levels < 5 µg/dL (7% reduction). 
However, when we restricted the analysis to 
those women who were more compliant, the 
reductions were similar between the women 
with higher (≥ 5 µg/dL = 17%) and lower 
(< 5 µg/dL = 14%) blood lead at baseline. 
Among those women with low compliance 
(< 50% of pills; n = 82), those with low 
baseline blood lead (< 5 µg/dL) appeared to 
experience a paradoxical effect of calcium on 
blood lead levels (an increase of 34%). Those 
who started the study with higher blood lead 
(≥ 5 µg/dL) showed the same average effects 
of treatment (17% reduction), although 
not statistically significant. Further analysis 
revealed, however, that the reported use of 
LGC in low compliers was higher among the 
calcium group (35%) than in the placebo 
group (27%), which may account for the 
apparent differences in treatment effect (7% 
vs. 17% reduction) observed in the intent-to-
treat analysis by baseline blood lead.
Discussion
In this randomized control trial, calcium 
supplementation (1,200 mg) was associated 
with modest reductions in blood lead levels 
when administered during pregnancy. These 
effects were clearly stronger with increasing 
compliance, with a 24% average reduction in 
the most compliant women, and strongest in 
those with baseline blood lead level > 5 µg/dL 
(17% average reduction). In the subset of most 
compliant women with high patella bone lead 
(> 5 µg/g) and reported use of LGC, we found 
the greatest reduction in blood lead of 31%, 
which corresponds to an average reduction of 
1.95 µg/dL (95% CI, –0.78 to –2.87).
These results are consistent with our pre-
viously published randomized trial, which 
showed that dietary calcium supplementation 
among postpartum women reduced mater-
nal blood lead by 15–20% over the course 
Table 4. Effect of calcium supplementationa by baseline blood lead level.
Baseline blood lead level  No. (calcium/placebo)  β-Coefficient  %Δb  p-Value
Among all women with follow-up (intent-to-treat analysis) 
  < 5 µg/dL  349 (183/166)  –0.07  –7%  0.08
  ≥ 5 µg/dL  208 (100/108)  –0.19  –17%  0.003
Among those women with compliance ≥ 50%c (as-treated analysis, among high compliers) 
  < 5 µg/dL  292 (162/130)  –0.15  –14%  0.01
  ≥ 5 µg/dL  183 (87/96)  –0.19  –17%  0.004
Among those women with compliance < 50%c (as-treated analysis, among low compliers) 
  < 5 µg/dL  57 (21/36)  0.29  34%  0.02
  ≥ 5 µg/dL  25 (13/12)  –0.18  –17%  0.49
aAdjusting for baseline blood lead level (log-transformed), maternal age, dietary calcium intake at baseline, daily energy 
intake at baseline, treatment group, and trimester of pregnancy. bPercent change; log-transformed outcome variable, 
thus estimate of treatment effect: 1 –e–β. cWe assessed compliance by pill count at each visit and analyzed as proportion 
of expected pills used between baseline (first trimester) and end of follow-up (8 months’ gestation).
Figure 3. Blood lead proportional reduction esti-
mates due to calcium supplementation (and 95% 
CIs), stratified by use of LGC (yes/no) and bone 
lead level (high/low) among the high-compliance 
group (≥ 75% of pills by pill count, adjusting for 
baseline blood lead, age, dietary calcium intake, 
daily energy intake, and trimester of pregnancy).
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of lactation (Hernández-Avila et al. 2003). 
In that study, the effect among women who 
were compliant with supplement use (≥ 50% 
of pills consumed) and had high bone lead 
(patella lead > 5 µg lead/g bone mineral) was 
an estimated reduction in mean blood lead of 
1.16 µg/dL (95% CI, –2.08 to –0.23).
These results are also consistent with the 
results of a study by Gulson et al. (2004) of 
blood lead isotopic ratios during pregnancy 
among women who had recently immigrated 
to Australia. The authors found that com-
pared with an earlier group of such women 
they had studied who had calcium-deficient 
diets, calcium-replete women had a rise in 
blood lead levels during pregnancy (with an 
isotopic fingerprint suggesting the lead came 
from bone) that occurred later in pregnancy 
and of a smaller magnitude. Although the use 
of lead isotopic ratios by Gulson et al. (2004) 
provided very rigorous and precise methodol-
ogy to their work, the interpretation with 
respect to calcium supplementation is limited 
by the small number of women (< 20) in 
their cases series [and thus limited statisti-
cal power to detect an association (Altman 
and Bland 1995)] and issues of comparability 
(e.g., the calcium-deficient women were stud-
ied at an earlier time and came from Central 
Europe, whereas the calcium-replete women 
were studied at a later time, came from Asia, 
and were otherwise not matched), making the 
results of our randomized placebo-controlled 
trial of particular interest.
The effect of calcium may be exerted, at 
least in part, by decreasing bone resorption and 
the consequent mobilization of maternal bone 
lead stores. In a case–crossover trial of calcium 
supplementation during the third trimester 
of pregnancy, we have previously shown that 
maternal bone resorption, as reflected by uri-
nary cross-linked N-telopeptide, was reduced 
by an average of 13.6 nM bone collagen equiv-
alents/mM creatinine (14%) compared with 
placebo (Janakiraman et al. 2003), indicating 
that calcium supplementation can suppress 
maternal bone mobilization.
The effects of calcium may also be attrib-
uted to decreasing the intestinal absorption 
of lead and/or increasing the excretion of lead 
from circulation. In the present study, we 
did not have prepregnancy bone lead levels, 
and Mexican laws forbidding potential radia-
tion exposure during pregnancy did not allow 
us to obtain bone lead measurements during 
pregnancy. However, our observation in the 
stratum of women with no reported LGC 
use—that the calcium effect is greater in those 
with high bone lead—suggests that, in this 
population, the effect may have been exerted 
mainly through inhibiting bone resorption.
Average baseline dietary calcium intake for 
women in our trials of Mexican women was 
less than the U.S. recommended dietary intake 
of 1,000–1,300 mg/day for pregnant and lac-
tating women (Institute of Medicine 1997). 
Levels of dietary calcium intake in our studies 
were, however, consistent with those reported 
in the Mexican National Nutrition Survey 
(Barquera et al. 2003) and in a nationally rep-
resentative sample of U.S. women of child-
bearing age (Lee et al. 2005). Hertz-Picciotto 
et al. (2000) followed 195 women over the 
course of pregnancy and found a U-shaped 
pattern of maternal blood lead concentration 
across pregnancy. The late pregnancy increases 
were steeper among women with low dietary 
calcium intake in both the low and high age 
groups, suggesting that lead redistribution 
may be more pronounced among pregnant 
women in calcium-deficient states. It is pos-
sible that high amounts of calcium are needed 
to counterbalance the nutritional needs of 
the developing fetus (Johnson 2001). Other 
genetic, hormonal, or lifestyle factors may also 
be involved (Ettinger et al. 2007).
Nonetheless, dietary calcium intake likely 
plays a limited, but still important, role in 
suppressing mobilization of lead from mater-
nal bone and/or decreasing gastrointestinal 
absorption of ingested lead, thereby decreas-
ing the risk of fetal and infant exposure. 
Calcium supplementation during pregnancy 
may also reduce the risk of hypertensive dis-
orders of pregnancy (Hofmeyr et al. 2007) 
that may also arise secondary to lead exposure 
(Rothenberg et al. 2002; Sowers et al. 2002) 
(and thus conferring additional negative 
effects of lead for both mother and fetus and 
a potential benefit of calcium supplementa-
tion). The risks posed by calcium supplemen-
tation at levels approximating recommended 
daily intakes in this population are negligible. 
We therefore conclude that dietary supple-
mentation of calcium intake should be con-
sidered as a cost-effective means for lowering 
transgenerational fetal lead exposure. This is 
particularly important in populations where 
dietary calcium intake is low. Because bone 
lead has a half-life of years to decades, women 
and their infants will continue to be at risk 
for exposure long after environmental sources 
of lead have been abated.
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